Approximately 600 patients expected to be enrolled at clinical sites across the United States, Europe, China and South America Global Phase 3 program, R...
Insilico Medicine ("Insilico," HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, announced that it has dosed the first patien...
Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late-breaking oral presentation at th...
Leveragen, Inc., a Boston-based biotechnology company advancing in vivo antibody discovery, today announced the grant of Australian Patent No. 2022271276...
The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients...
FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027 Positions lonvo-z to be the world’s first in vivo CRISPR-based therapy an...
Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for s...
Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagen...
-Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced a collaboration with Aceso Therapeutics, a...
HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options ...
Rezubio announced that it has successfully completed dosing of the first cohort in its Phase 1 clinical trial following clearances from the US FDA a...
Novartis announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of red...
Thryv Therapeutics Inc. ("Thryv"), a clinical-stage biopharmaceutical company advancing selective SGK1 inhibitors, announced that it has entered into an ...
Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced the Phase Ib/IIa clinical results of its anti-S...
© 2026 Biopharma Boardroom. All Rights Reserved.
